February 14, 2018 09:10 AM EST

Stock slumps for Tel Aviv's Galmed following PhIIa NAFLD flop

Brittany Meiling

The stock price is cratering for thinly-traded Tel Aviv company Galmed Pharmaceuticals $GLMD, which just announced a Phase IIa letdown of its non-alcoholic fatty liver …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Stock slumps for Tel Aviv's Galmed following PhIIa NAFLD flop

Brittany Meiling

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Are programs with compounded GLP-1s safe for your population?

Stock slumps for Tel Aviv's Galmed fol­low­ing PhI­Ia NAFLD flop

Brittany Meiling

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Stock slumps for Tel Aviv's Galmed following PhIIa NAFLD flop

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Are programs with compounded GLP-1s safe for your population?